JP2022515152A5 - - Google Patents

Info

Publication number
JP2022515152A5
JP2022515152A5 JP2021535665A JP2021535665A JP2022515152A5 JP 2022515152 A5 JP2022515152 A5 JP 2022515152A5 JP 2021535665 A JP2021535665 A JP 2021535665A JP 2021535665 A JP2021535665 A JP 2021535665A JP 2022515152 A5 JP2022515152 A5 JP 2022515152A5
Authority
JP
Japan
Prior art keywords
seq
recombinant protein
protein according
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067563 external-priority patent/WO2020132291A1/en
Publication of JP2022515152A publication Critical patent/JP2022515152A/ja
Publication of JP2022515152A5 publication Critical patent/JP2022515152A5/ja
Priority to JP2024192700A priority Critical patent/JP2025032075A/ja
Pending legal-status Critical Current

Links

JP2021535665A 2018-12-19 2019-12-19 Baff-r二重特異性t細胞エンゲージャー抗体 Pending JP2022515152A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024192700A JP2025032075A (ja) 2018-12-19 2024-11-01 Baff-r二重特異性t細胞エンゲージャー抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782317P 2018-12-19 2018-12-19
US62/782,317 2018-12-19
PCT/US2019/067563 WO2020132291A1 (en) 2018-12-19 2019-12-19 Baff-r bispecific t-cell engager antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024192700A Division JP2025032075A (ja) 2018-12-19 2024-11-01 Baff-r二重特異性t細胞エンゲージャー抗体

Publications (2)

Publication Number Publication Date
JP2022515152A JP2022515152A (ja) 2022-02-17
JP2022515152A5 true JP2022515152A5 (cg-RX-API-DMAC7.html) 2022-12-21

Family

ID=71098268

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535665A Pending JP2022515152A (ja) 2018-12-19 2019-12-19 Baff-r二重特異性t細胞エンゲージャー抗体
JP2024192700A Pending JP2025032075A (ja) 2018-12-19 2024-11-01 Baff-r二重特異性t細胞エンゲージャー抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024192700A Pending JP2025032075A (ja) 2018-12-19 2024-11-01 Baff-r二重特異性t細胞エンゲージャー抗体

Country Status (8)

Country Link
US (2) US20200199232A1 (cg-RX-API-DMAC7.html)
EP (1) EP3897720A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022515152A (cg-RX-API-DMAC7.html)
KR (1) KR20210104816A (cg-RX-API-DMAC7.html)
CN (2) CN113412124A (cg-RX-API-DMAC7.html)
AU (1) AU2019404282A1 (cg-RX-API-DMAC7.html)
CA (1) CA3123599A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020132291A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN116997573A (zh) * 2020-10-15 2023-11-03 佳努克斯治疗公司 靶向psma和cd3的抗体及其用途
US20240034807A1 (en) * 2021-02-16 2024-02-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to mesothelin polypeptides
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
JP2025523874A (ja) * 2022-07-19 2025-07-25 ノバルティス アーゲー Baff又はbaff受容体阻害抗体でのaihaの治療
WO2024074145A1 (zh) * 2022-10-08 2024-04-11 盛禾(中国)生物制药有限公司 一种结合baffr和cd3的双特异性抗体及其应用
CN121464157A (zh) * 2023-02-28 2026-02-03 梅约医学教育与研究基金会 结合至b细胞活化因子受体多肽的分子
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4733635B2 (ja) * 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
SMT201800335T1 (it) * 2012-11-06 2018-09-13 Bayer Pharma AG Formulazione di attivatori bispecifici per linfociti t (bite)
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
ES2980787T3 (es) * 2014-07-31 2024-10-03 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
EP3778640A1 (en) * 2015-05-01 2021-02-17 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
EP3310811B1 (en) * 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
UA126657C2 (uk) * 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
US11136405B2 (en) * 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
EP3464371B1 (en) * 2016-06-06 2026-07-29 City of Hope Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
AU2017337073A1 (en) * 2016-09-30 2019-04-18 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
KR20210129125A (ko) * 2019-02-20 2021-10-27 시티 오브 호프 Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2024020298A5 (cg-RX-API-DMAC7.html)
JP2024167313A5 (cg-RX-API-DMAC7.html)
JP2025111463A5 (cg-RX-API-DMAC7.html)
JP2024096688A5 (cg-RX-API-DMAC7.html)
JP2023081303A5 (cg-RX-API-DMAC7.html)
JP2020180158A5 (cg-RX-API-DMAC7.html)
JP2023058573A5 (cg-RX-API-DMAC7.html)
JP2020521448A5 (cg-RX-API-DMAC7.html)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2019535763A5 (cg-RX-API-DMAC7.html)
CN116396386A (zh) Cd3抗体及其药物用途
JP2018517431A5 (cg-RX-API-DMAC7.html)
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2019502712A5 (cg-RX-API-DMAC7.html)
JP2020522474A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2018193386A5 (cg-RX-API-DMAC7.html)
JP2010526028A5 (cg-RX-API-DMAC7.html)
JP2007532139A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2013519364A5 (cg-RX-API-DMAC7.html)
JP2020522254A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2021520393A5 (cg-RX-API-DMAC7.html)